2 min read
The Colombian healthcare system prioritizes patient safety and access to effective medicines. To support these objectives, the National Institute of Drug and Food Surveillance (INVIMA) acts as the central regulatory authority overseeing the drug approval process in Colombia.
This blog serves as a practical guide, addressing 15 frequently asked questions (FAQs) about drug registration and approval in Colombia, helping pharmaceutical companies better understand INVIMA requirements and regulatory expectations.
1. Who can submit a drug for approval in Colombia?
Pharmaceutical companies, research institutions, individual applicants (natural persons), or their Authorized Representatives (ARs) may submit applications before INVIMA.
2. What are the main steps in the drug approval process in Colombia?
The process typically includes preclinical and clinical development, dossier preparation, application submission, technical review by INVIMA, and, when applicable, inspections.
3. Can traditional or herbal medicines be approved in Colombia?
Yes. INVIMA provides a specific regulatory pathway to evaluate the safety and quality of traditional and herbal medicines.
4. Is foreign approval (US or EU) sufficient for Colombia?
No. While prior approvals may support the application, a separate INVIMA submission is required, using data relevant to the Colombian context.
5. What fees apply to drug applications?
INVIMA charges regulatory fees depending on the type and complexity of the drug application.
6. What documentation is required?
Applicants must submit a complete regulatory dossier, including product information, manufacturing details, and clinical trial data, as applicable.
7. Can I track my application status?
Yes. INVIMA offers digital tools that allow applicants to monitor the progress of their submissions.
8. What happens if the application is rejected?
INVIMA provides feedback outlining deficiencies, allowing applicants to address observations and resubmit the application.
9. Are there expedited pathways for innovative medicines?
Yes. INVIMA offers evaluation mechanisms for medicines addressing unmet medical needs or life-threatening conditions.
10. What are post-approval obligations?
Marketing authorization holders must comply with pharmacovigilance and post-market surveillance requirements.
11. Can unapproved drugs be imported into Colombia?
Limited exceptions exist through compassionate use programs, mainly for critically ill patients.
12. Are there specific requirements for pediatric drugs?
Yes. INVIMA applies strict safety and efficacy requirements for medicines intended for pediatric populations.
13. Where can I verify approved drugs in Colombia?
INVIMA maintains a public database of authorized medicines, accessible to stakeholders.
14. What ethical standards apply to clinical trials?
INVIMA enforces ethical requirements ensuring informed consent and participant protection.
15. Are there cost-saving options for smaller companies?
Yes. Reduced fees and streamlined processes may apply to small and medium-sized enterprises developing essential or generic drugs.
Navigating the drug approval process in Colombia requires a solid understanding of INVIMA’s regulatory framework and expectations. With the right regulatory strategy, companies can ensure compliance while accelerating market access.
Partnering with an experienced regulatory provider can help streamline INVIMA submissions and reduce approval timelines. Contact our regulatory experts to support your INVIMA drug approval strategy in Colombia.
